Biovail (BVF) Confirms Receipt Of Notification Of ANDA Submission For Wellbutrin XL; BVF Stock Down
10/19/2005 5:12:14 PM
Biovail Corporation (NYSE:BVF)(TSX:BVF) today confirmed that it has received notification that an abbreviated new drug application (ANDA) has been submitted to the U.S. Food and Drug Administration (FDA) by Anchen Pharmaceuticals, Inc., seeking marketing approval for 150mg and 300mg generic formulations of Wellbutrin XL(R) (once-daily bupropion). At the present time, it is not known if the ANDA submission has been accepted for review by the FDA.
comments powered by